Global Novel Drug Delivery Systems (NDDS) Industry

Global Novel Drug Delivery Systems (NDDS) Industry

  • April 2021 •
  • 112 pages •
  • Report ID: 5957531 •
  • Format: PDF
Abstract:
- Global Novel Drug Delivery Systems (NDDS) Market to Reach $27.2 Billion by 2027
- Amid the COVID-19 crisis, the global market for Novel Drug Delivery Systems (NDDS) estimated at US$7.7 Billion in the year 2020, is projected to reach a revised size of US$27.2 Billion by 2027, growing at aCAGR of 19.7% over the period 2020-2027. Nanoparticles, one of the segments analyzed in the report, is projected to record 19% CAGR and reach US$23.2 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Embolization Particles segment is readjusted to a revised 24.7% CAGR for the next 7-year period.
- The U.S. Market is Estimated at $2.3 Billion, While China is Forecast to Grow at 19.3% CAGR
- The Novel Drug Delivery Systems (NDDS) market in the U.S. is estimated at US$2.3 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$4.8 Billion by the year 2027 trailing a CAGR of 19.3% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 17.4% and 16.8% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 13.8% CAGR.

- Select Competitors (Total 46 Featured) -
  • Abbott Laboratories
  • AstraZeneca PLC
  • Bayer HealthCare Pharmaceuticals
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis International AG
  • Pfizer, Inc.